Use of Immunotherapy in Acute Myeloid Leukemia
DOI:
https://doi.org/10.58445/rars.2533Keywords:
AML, Immunotherapy, LILRB4, CD33, Dendritic Cell Therapy, Acute Myeloid LeukemiaAbstract
AML is a blood cancer in which genetic mutations occur in precursor myeloid cells, which in turn, causes defects in white cell maturation. Immunotherapy treatments for AML are currently in the clinical trial stages but allogeneic hematopoietic stem cell transplantation (HSCT) is the most successful immunotherapies as of now, Antibody-Drug Conjugate immunotherapies, Dendritic cell vaccination, and ICIs have shown to be successful in early stage clinical trials. Immunotherapy has been a very beneficial form of treatment, especially for patients above the age of 60, who are in the post-relapse stages. Currently, researchers in the field of immunotherapy for AML are working on developing these treatments in order to progress to the clinical trial stages and looking further into combinations of different immunotherapies to treat AML. There are some obstacles to face such as AML not having enough specific antigens to be targeted and the lack of attention for pediatric AML cases. In the future, immunotherapy seems to be a promising treatment for AML as it has already shown success in current studies, and it is a working preventative for relapsing, elderly patients.
References
Acharya, U. H., Halpern, A. B., Wu, Q., Voutsinas, J. M., Walter, R. B., Yun, S., ... & Estey, E. H. (2018). Impact of region of diagnosis, ethnicity, age, and gender on survival in acute myeloid leukemia (AML). Journal of drug assessment, 7(1), 51-53.
Aung, M. M. K., Mills, M. L., Bittencourt-Silvestre, J., & Keeshan, K. (2021). Insights into the molecular profiles of adult and paediatric acute myeloid leukaemia. Molecular oncology, 15(9), 2253–2272. https://doi.org/10.1002/1878-0261.12899
Aureli, A., Marziani, B., Sconocchia, T., Del Principe, M. I., Buzzatti, E., Pasqualone, G., Venditti, A., & Sconocchia, G. (2021). Immunotherapy as a Turning Point in the Treatment of Acute Myeloid Leukemia. Cancers, 13(24), 6246. https://doi.org/10.3390/cancers13246246
Dean, L., & Dean, L. (2005). Blood groups and red cell antigens (Vol. 2). Bethesda: NCBI.
Deng, M., Gui, X., Kim, J., Xie, L., Chen, W., Li, Z., He, L., Chen, Y., Chen, H., Luo, W., Lu, Z., Xie, J., Churchill, H., Xu, Y., Zhou, Z., Wu, G., Yu, C., John, S., Hirayasu, K., Nguyen, N., … Zhang, C. C. (2018). LILRB4 signalling in leukaemia cells mediates T cell suppression and tumour infiltration. Nature, 562(7728), 605–609. https://doi.org/10.1038/s41586-018-0615-z
Gómez-Llobell, M., Peleteiro Raíndo, A., Climent Medina, J., Gómez Centurión, I., & Mosquera Orgueira, A. (2022). Immune Checkpoint Inhibitors in Acute Myeloid Leukemia: A Meta-Analysis. Frontiers in oncology, 12, 882531. https://doi.org/10.3389/fonc.2022.882531
Jaramillo S, Schlenk RF. Update on current treatments for adult acute myeloid leukemia: to treat acute myeloid leukemia intensively or non-intensively? That is the question. Haematologica 2023;108(2):342-352; https://doi.org/10.3324/haematol.2022.280802.
Khaldoyanidi, S., Nagorsen, D., Stein, A., Ossenkoppele, G., & Subklewe, M. (2021). Immune Biology of Acute Myeloid Leukemia: Implications for Immunotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 39(5), 419–432. https://doi.org/10.1200/JCO.20.00475
Levy, B., Baughn, L. B., Akkari, Y., Chartrand, S., LaBarge, B., Claxton, D., ... & Broach, J. R. (2023). Optical genome mapping in acute myeloid leukemia: a multicenter evaluation. Blood advances, 7(7), 1297-1307.
Li, M., & Zhao, X. (2024). LILRB4 in acute myeloid leukemia: From prognostic biomarker to immunotherapeutic target. Chinese Medical Journal. https://doi.org/10.1097/cm9.0000000000003195
Lichtenegger, F. S., Krupka, C., Haubner, S., Köhnke, T., & Subklewe, M. (2017). Recent developments in immunotherapy of acute myeloid leukemia. Journal of hematology & oncology, 10, 1-20.
Muenst, S., Läubli, H., Soysal, S. D., Zippelius, A., Tzankov, A., & Hoeller, S. (2016). The immune system and cancer evasion strategies: therapeutic concepts. Journal of internal medicine, 279(6), 541-562.
Oran B, Weisdorf DJ. Survival for older patients with acute myeloid leukemia: a population-based study. Haematologica. 2012 Dec;97(12):1916-24. doi: 10.3324/haematol.2012.066100. Epub 2012 Jul 6. PMID: 22773600; PMCID: PMC3590098.
Palomares, F., Pina, A., Dakhaoui, H., Leiva-Castro, C., Munera-Rodriguez, A. M., Cejudo-Guillen, M., Granados, B., Alba, G., Santa-Maria, C., Sobrino, F., & Lopez-Enriquez, S. (2024). Dendritic Cells as a Therapeutic Strategy in Acute Myeloid Leukemia: Vaccines. Vaccines, 12(2), 165. https://doi.org/10.3390/vaccines12020165
Panuzzo, C., Signorino, E., Calabrese, C., Ali, M. S., Petiti, J., Bracco, E., & Cilloni, D. (2020). Landscape of Tumor Suppressor Mutations in Acute Myeloid Leukemia. Journal of clinical medicine, 9(3), 802. https://doi.org/10.3390/jcm9030802
Park, J. A., & Cheung, N. V. (2017). Limitations and opportunities for immune checkpoint inhibitors in pediatric malignancies. Cancer treatment reviews, 58, 22–33. https://doi.org/10.1016/j.ctrv.2017.05.006
Pelcovits, A., & Niroula, R. (2020). Acute myeloid leukemia: a review. Rhode Island medical journal, 103(3), 38-40.
Van Acker, H. H., Versteven, M., Lichtenegger, F. S., Roex, G., Campillo-Davo, D., Lion, E., Subklewe, M., Van Tendeloo, V. F., Berneman, Z. N., & Anguille, S. (2019). Dendritic Cell-Based Immunotherapy of Acute Myeloid Leukemia. Journal of clinical medicine, 8(5), 579. https://doi.org/10.3390/jcm8050579
Williams, G. H., & Stoeber, K. (2012). The cell cycle and cancer. The Journal of pathology, 226(2), 352-364.
Xiangyu Zhao, Meng Lv, Yu Wang, Yi-Yang Ding, Zhixiao Zhou, Jiasheng Wang, HongLi Zheng, Xueqiang Zhao, Xin Lin, Xiao Jun Huang; LILRB4 Synthetic T-Cell Receptor and Antigen Receptor-T (STAR-T) for Refractory/Relapsed Acute Myeloid Leukemia: First-in-Human Phase I Clinical Trial. Blood 2024; 144 (Supplement 1): 4831. doi: https://doi.org/10.1182/blood-2024-207297
Zhong, X., & Ma, H. (2022). Targeting CD38 for acute leukemia. Frontiers in Oncology, 12. https://doi.org/10.3389/fonc.2022.1007783
NCT03697707
NCT05662904
Downloads
Posted
Categories
License
Copyright (c) 2025 Aarya Sharma
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.